In this video interview, Krinx Kong, chief commercial officer, Cognivia, highlights how patients’ perspectives on vaccine trials may shift if a policy change was to take place.
In a recent video interview with Applied Clinical Trials, Krinx Kong, chief commercial officer, Cognivia, discussed the potential impacts of policy shifts on vaccine trial design and patient perceptions. Stricter regulations could increase trial complexity, affecting recruitment and retention. Kong emphasized behavioral insights as crucial to understanding patient motivation and mitigating dropouts. Looking forward with the potential for policy changes in vaccine trials, clinical operations professionals must focus on flexibility, behavioral visibility, and effective communication to ensure success.
ACT: There are already challenges with how patients perceive clinical research. From their point of view, how could a potential policy shift with vaccine trials further affect perception and trust?
Kong: Vaccine trials are already subject to intense public scrutiny and often misunderstanding. Therefore, when political or policy discussions suggest a new use of placebo controls, even though they've been long been the gold standard, it can create confusion. From the patient's perspective, this can sound like researchers are just now deciding to withhold treatment, which naturally triggers concern or mistrust. The truth is, placebo use is well governed and deeply rooted in evidence-based medicine. However, perception is everything nowadays. If patients or the public believe vaccine trials are less transparent or less ethical, that perception alone can damage trust, and we're seeing that today. That's why it's imperative to consider behavioral insights as a core aspect of trial success. Sponsors need to understand how participants interpret trial protocols, not just whether they follow them. This understanding helps trial teams communicate more clearly, empathetically, and persuasively, so patients feel safe, informed, and valued, even in a complex or high-profile trial in the era of misinformation, perception is no longer a side issue. It's central to both enrollment and impact.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.